Cardea Bio is developing biology-based transistors for linking biology directly up to computers. These transistors leverage graphene and are designed to replace optical static observations with interactive live-streams of multi-omics signal analysis, representing a new life science observation paradigm according to the company, where multi-omics data-streams will be the new norm instead of most of the current standard technologies that are single-omics frozen-in-time datasets.

The company’s approach of linking biology directly to compute power and converting real-time biological signals to digital information allows for immediate biological insight that can power a new generation of applications across human health, agriculture, food and water safety, diagnostics, biosafety, and the environment.

Innovation: Biology-based transistors that are used as Digital Biosensors, designed to replace optical static observations with interactive live-streams of multi-omics signal analysis.

Potential application areas: Human health, agriculture, food and water safety, diagnostics, biosafety, and the environment.

The company recently launched the CRISPR-Chip™, that is built with its proprietary Cardean Transistors. The chipset uses CRISPR as the transistor gate, and thereby harvests CRISPR’s powerful natural ability to search through genomes for genetic sequences of interest. This is all accomplished without the need of PCR/DNA amplification, enabling the user to observe the CRISPR search activity and results live on a computer screen.

The CRISPR-Chip is one of multiple chipsets Cardea offers its partners via the Cardea Innovation Partnership Program, which is the core of the Company’s business model. The company expects a number of “Powered by Cardea” products to launch in 2020 and 2021.

Subscribe for alerts on new companies featured on Startups.Bio

• U-Ploid BiotechnologiesSeptember 17, 2024
  U-Ploid Biotechnologies aims to revolutionize IVF for Age-Related Infertility. Millions of women… Read more: U-Ploid Biotechnologies
• BioTryp TherapeuticsMarch 22, 2024
  BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on… Read more: BioTryp Therapeutics
• Bastion TherapeuticsJanuary 9, 2024
  Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class… Read more: Bastion Therapeutics
• HOVANANovember 22, 2023
  HOVANA is a digital biology company tackling translational dysfunction as a driver… Read more: HOVANA